Introditctiori
Antibodies are important molecules in immune defence. With the development of monoclonal antibody and genetic engineering technologies, the use of antibodies in a controlled manner in the therapy of human disease appears as an attainable goal. However, this will require a detailed undcrstanding of the structure-function relationships of the various immunoglobulin molecules.
In essence, antibodies can be seen as fulfilling their protcctive role by two molecular recognition processes. The first is that of antigen, which has received much attention and reaches a new level of understanding with the solution of crystal structures for antigen-antibody fragment complexes (Amit et al., 1986; Colman et al., 1987) . The second process is the recognition of antibody by effector molecules such as complement C 1 or cellular receptors, thereby triggering elimination of the antigen-bearing entity (Burton, 1985) . The basis for this second effector phase of antibody action is only now being tackled at the molecular level.
Effector molecules interact with the Fc part of the antibody molecule and crystallographic structures are available for isolated Fc fragments from human (Deisenhofer, 198 1 ) and rabbit IgG (Sutton & Phillips, 1983) . Fig. 1 shows the structure of human Fc and illustrates the pairing of the CH3 domains and the interposition of two branched Winked oligosaccharides between the two CH2 domains.
Complement activation
The classical pathway of complement is a cascade system generating a variety of potent biological molecules including anaphylatoxins and chemoattractants and leading ultimately to lysis of antibody-coated cells (Reid & Porter, 198 1 ; Reid, 1983) . In health, foreign cells will be the primary target. In disease, host tissue may be attacked on a large scale, e.g. in autoimmune disorders. The pathway is triggered by the interaction of the first complement component, C1, with IgG in an associated state, i.e. coating a target cell or aggregated by antigen in an immune complex. The pathway is clearly not triggered by monomeric IgG which is at high concentration in the serum.
C 1 is a complex of the complement components C I q, C 1 r and Cls. It is the subcomponent C l q which interacts with the C,2 domain of IgG to initiate the enzymic process of the athway. C l q is a molecule having the appearance of a ! I unch of tulips' (Reid & Porter, 198 318, 320, 322, 331, 333, 335, 337) are represented.
cess to proceed (Burton, 108.5). Theories of activation which involve binding of antigen to the Fab arms of IgG and the induction of conformational changes which are passed down the molecule to Fc, thus affecting the interaction with Clq. are now rejected by most workers (Metzger, 1978) . There is general agreement about the importance of charged groups in the interaction of IgG and C l q , but there has been controversy over the precise location of the C l q binding site on IgG. The domain responsible for C l q binding is concluded to be CH2 (Colomb & Porter, 1975) as the Fab fragment of rabbit IgG (lacking the CH3 domains) binds CI with an affinity comparable to IgG and isolated cH2 domains bind C1 with an affinity comparable to Fc (Yasmeen et al., 1976) . Three groups of workers proposed C l q binding sites on the CH2 domain around about 1980 as illustrated in Fig. 1 . Recent protein engineering studies by Winter and colleagues suggest that three charged residues in the site of Burton et al. (1980) are critical for C l q binding (A. R. Duncan & G. Winter, personal communication) . At first sight it may appear surprising that such an important interaction should involve such a limited motif. However, it should be borne in mind that the interaction of one C l q head and Fc is weak as discussed above and the possibility of a limited site was foreseen. '(The site may require) only the presence of a small number of adjacent charged groups and a relatively small hydrophobic re&' Tion to achieve the required binding energy.. . . C l q would be expected to interact with a variety of molecules -the antibody molecule would distinguish itself in an immune aggregate or on a cell surface by the close proximity of other antibody molecules allowing the multivalent nature of C l q to come into play and greatly enhance affinity ' (Burton, 1985) .
Ce l l 11 lar recognition
Receptors for the Fc region of IgG are found on a number of cell types and are associated with a variety of functions including phagocytosis ( monocytes, macrophages, neutrophils), antibody-dependent cellular cytotoxicity (monocytes, macrophages, lymphocytes), maternofetal transport (trophoblasts) and possibly immunomodulation (lymphocytes). 'Fc receptor' is an operational term and does not imply the same molecular species is found on the different cell types. Indeed there is good evidence that a number of molecular species are involved (reviewed by Anderson & Looney, 1986 ). We The model is proposed primarily on the basis of a comparison of sequences of IgG of different species and subclass showing differing affinity for monocyte FcRI (Woof et al., 1986) . The region of interaction on Fc is suggested to involve that between the interheavy disulphdes and the folded cH2 domain. The monocyte Fc receptor has a molecular mass of approximately 70000 Da and is represented as a globular protein of appropriate size. An antigenic surface is included in the diagram to show the close approach of foreign cell and monocyte required by the interaction, although most studies have been carried out using unliganded monomeric IgG.
have been particularly concerned with the molecular basis for the interaction of the high-affinity human monocyte Fc receptor (FcFU) and IgG. Until recently, the conventional wisdom was that complement interacts with the CH2 domain and cellular receptors with the CH3 domain of IgG. However, using immunoaffinity purified proteolytic fragments of IgG (Woof ef al.. 1984) and domain-specific anti-Fc monoclonal antibodies (Partridge et al., 1986) , we were able to show that FcRl was probably interacting with the CH2 domain. Based on a sequence comparison of lgGs showing differing affinity for FcRl, we proposed a receptor site at the extreme N-terminal end of Fc involving residues between the hinge disulphide and the 
Monocyte
folded C,,2 domain (hinge link or lower hinge, Fig. 2 and This site receives support from a protein engineering experiment carried out by Winter & Duncan in Cambridge and this laboratory (Duncan et ul.. 1988) . Briefly Glu-235 in the non-receptor binding mouse IgG2b antibody was engineered t o LCU t o give it a sequence identical in the proposed site with the tight binding mouse IgG2a or human IgG1 antibodies ( Table 1 ) . This Glu -Leu 235 mutant was found t o show tight receptor binding.
Interestingly. the site of mast ccll binding t o IgE has been suggested t o be in a roughly equivalent position to that discussed for IgG at the N-terminal extremities of the Fc (Helm Table 1 ) (Woof ('I at.. 1986 ).
eta/., 1988).

1)islocuted r r i o c i d of'aritihody efec.torfirrictiori
Simultaneous binding of antibody to host cell receptor and foreign cell antigen is easily envisaged if the former occurs at the 'bottom' of Fc (C,,3 domains) and the latter at the 'tops' of the Fab arms (IV domains). However, the binding of cell receptor t o the 'top' of the Fc presents topological problems when antibody is at the same time in interaction with antigen. I have proposed that in such situations antibody is dislocated (Burton. 1986) . In other words, hinge flexibility is exploited t o dislocate the Fab arms out of the plane of the Fc to lead to the type of model envisaged in Fig. 3(u) . Support for the ability of antibodies to dislocate comes from two-dimensional crystallization studies on IgG (Reidler et ut., 1986) and fluorescence energy transfer studies on IgE bound to basophi1 cells (Holowka & Baird, 1Y83). Fig. 3 ( u ) also includes the hypothesis of Fc-Fc interaction for which there is some evidence at cell surfaces F(ab')? arms are dislocatcd out of the plane of the (Fc), disc to give a molecule resembling a 'staple'. This star-to-staple transition appears sufficient to allow complement C 1 binding and activation of IgM. T h e mechanism appears to be distortional (e.g. exposure of sites in the staple form) rather than allosteric, i.e. involving conformational changes passed through the molecule to Fc on antigen binding. T h e dislocated model for IgG can easily be extended to the interaction with complement (Fig. 3h) and provides a view whereby the two antibodies IgG and IgM solve the physiological problem of activating complement when in contact with antigen, but not when free in serum, by two different routes arriving at a similar destination. Monomer serum IgG molecules rely on antigen to bring Fc regions together, the relationship being cemented by Fc-Fc interaction in a dislocated arrangement. In pentameric star-shaped serum IgM, Fc regions are already close, but in inactive form. Binding t o antigen dislocatcs the molecule to produce an active form.
Clearly the types of model discussed above will require experimental verification o r otherwise. However, it seems a good guess to suppose that, as antibody function is dissected, common motifs will emerge that reflect the common origins of this unique family of versatile proteins. Steensgaard, 1984) . [264] [265] [266] in the
